CarboHealth, also known under the name CCC3, started in 2013 and has been completed at the end of 2017. CarboHealth aims to develop a toolbox to support the European Food Safety Authority (EFSA) in substantiating health claims regarding dietary fibre. CarboHealth is conducting fundamental and demand-driven research on the effects of known and potential new prebiotics on human intestinal flora.
Knowledge institutes and businesses have joined hands in CarboHealth to stimulate and dig deeper into knowledge on the role of starches and carbohydrates in health. The aim is to make meaningful contributions to healthier societies and to subjects like Healthy Ageing, but while doing so also generating added value for CCC partners. CarboHealth has a program volume of €3.3 million, €1.7 million of which is private investment (cash and in-kind).
Six business enterprises are participating in the consortium – FrieslandCampina, AVEBE, Sensus, Nutreco, Winclove and Danone Nutricia – alongside four knowledge institutes – WUR, UG, UMCG and DLO-FBR.
Presentation introduction symposium 30-11-2017
Research Presentations symposium 30-11-2017
- Exploring the impact of pre- and probiotics on intestinal barrier function by Nicole de Wit
- Human milk oligosaccharides by Sander van Leeuwen
- In vitro and in vivo fermentation behaviour of prebiotic carbohydrates by Fangjie Gu
- Modulating the gut microbiota for better health by Klaudyna Borewicz
- Immune effects of selected pre- and probiotics and efficacy in enhancing oral vaccination against Salmonella Typhimurium by Alexia Lépine
- Assessing metabolic health effects of carbohydrates in vivo by Rima Mistry
- The role of selected probiotic bacteria in degradation of (prebiotic) carbohydrates by Markus Böger